Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis

被引:38
作者
Leung, Amy [1 ,2 ,3 ,8 ,9 ]
Nah, Shirley K. [1 ,2 ,3 ,8 ,9 ]
Reid, Whitney [1 ,2 ,3 ,8 ,9 ]
Ebata, Atsushi [4 ,5 ]
Koch, Clarissa M. [6 ]
Monti, Stefano [1 ,2 ,3 ]
Genereux, Joseph C. [7 ]
Wiseman, R. Luke [7 ]
Wolozin, Benjamin [4 ,5 ]
Connors, Lawreen H. [6 ]
Berk, John L. [6 ]
Seldin, David C. [1 ,2 ,3 ,6 ]
Mostoslavsky, Gustavo [8 ,9 ]
Kotton, Darrell N. [8 ,9 ]
Murphy, George J. [1 ,2 ,3 ,8 ,9 ]
机构
[1] Boston Univ, Sch Med, Dept Med, Hematol Oncol Sect, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Med, Sect Computat Biomed, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA
[4] Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA
[5] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA
[6] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA 02118 USA
[7] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[8] Boston Univ, Sch Med, Ctr Regenerat Med, Boston, MA 02118 USA
[9] Boston Med Ctr, Boston, MA 02118 USA
关键词
CARDIAC AMYLOIDOSIS; HEPATIC ENDODERM; TRANSGENIC MICE; IPS CELLS; POLYNEUROPATHY; DEPOSITION; DIFFERENTIATION; VARIANT; MOUSE; GENERATION;
D O I
10.1016/j.stemcr.2013.10.003
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Familial transthyretin amyloidosis (ATTR) is an autosomal-dominant protein-folding disorder caused by over 100 distinct mutations in the transthyretin (TTR) gene. In ATTR, protein secreted from the liver aggregates and forms fibrils in target organs, chiefly the heart and peripheral nervous system, highlighting the need for a model capable of recapitulating the multisystem complexity of this clinically variable disease. Here, we describe the directed differentiation of ATTR patient-specific iPSCs into hepatocytes that produce mutant TTR, and the cardiomyocytes and neurons normally targeted in the disease. We demonstrate that iPSC-derived neuronal and cardiac cells display oxidative stress and an increased level of cell death when exposed to mutant TTR produced by the patient-matched iPSC-derived hepatocytes, recapitulating essential aspects of the disease in vitro. Furthermore, small molecule stabilizers of TTR show efficacy in this model, validating this iPSC-based, patient-specific in vitro system as a platform for testing therapeutic strategies.
引用
收藏
页码:451 / 463
页数:13
相关论文
共 52 条
[1]   Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy [J].
Ackermann, Elizabeth J. ;
Guo, Shuling ;
Booten, Sheri ;
Alvarado, Luis ;
Benson, Merrill ;
Hughes, Steve ;
Monia, Brett P. .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2012, 19 :43-44
[2]   Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity [J].
Alhamadsheh, Mamoun M. ;
Connelly, Stephen ;
Cho, Ahryon ;
Reixach, Natalia ;
Powers, Evan T. ;
Pan, Dorothy W. ;
Wilson, Ian A. ;
Kelly, Jeffery W. ;
Graef, Isabella A. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (97)
[3]   Transthyretin-related familial amyloidotic polyneuropathy [J].
Ando, Y ;
Nakamura, M ;
Araki, S .
ARCHIVES OF NEUROLOGY, 2005, 62 (07) :1057-1062
[4]   SYSTEMIC AMYLOIDOSIS IN TRANSGENIC MICE CARRYING THE HUMAN MUTANT TRANSTHYRETIN (MET-30) GENE - PATHOLOGICAL AND IMMUNOHISTOCHEMICAL SIMILARITY TO HUMAN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY, TYPE-I [J].
ARAKI, S ;
YI, S ;
MURAKAMI, T ;
WATANABE, S ;
IKEGAWA, S ;
TAKAHASHI, K ;
YAMARNURA, K .
MOLECULAR NEUROBIOLOGY, 1994, 8 (01) :15-23
[5]   Rate of Progression of Transthyretin Amyloidosis [J].
Benson, Merrill D. ;
Teague, Shawn D. ;
Kovacs, Richard ;
Feigenbaum, Harvey ;
Jung, Jeesun ;
Kincaid, John C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (02) :285-289
[6]   The Diflunisal Trial: Study accrual and drug tolerance [J].
Berk, John L. ;
Suhr, Ole B. ;
Sekijima, Yoshiki ;
Yamashita, Taro ;
Heneghan, Michael ;
Zeldenrust, Steven R. ;
Ando, Yukio ;
Ikeda, Shu-ichi ;
Gorevic, Peter ;
Merlini, Giampaolo ;
Kelly, Jeffrey W. ;
Skinner, Martha ;
Bisbee, Alice B. ;
Dyck, Peter J. ;
Obici, Laura .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2012, 19 :37-38
[7]   Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? [J].
Buxbaum, Joel N. ;
Tagoe, Clement ;
Gallo, Gloria ;
Walker, John R. ;
Kurian, Sunil ;
Salomon, Daniel R. .
FASEB JOURNAL, 2012, 26 (06) :2283-2293
[8]   Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models [J].
Cardoso, Isabel ;
Martins, Diana ;
Ribeiro, Tania ;
Merlini, Giampaolo ;
Saraiva, Maria Joao .
JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
[9]   Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling [J].
Chambers, Stuart M. ;
Fasano, Christopher A. ;
Papapetrou, Eirini P. ;
Tomishima, Mark ;
Sadelain, Michel ;
Studer, Lorenz .
NATURE BIOTECHNOLOGY, 2009, 27 (03) :275-280
[10]   Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial [J].
Coelho, Teresa ;
Maia, Luis F. ;
da Silva, Ana Martins ;
Cruz, Marcia Waddington ;
Plante-Bordeneuve, Violaine ;
Lozeron, Pierre ;
Suhr, Ole B. ;
Campistol, Josep M. ;
Conceicao, Isabel Maria ;
Schmidt, Hartmut H. -J. ;
Trigo, Pedro ;
Kelly, Jeffery W. ;
Labaudinie, Richard ;
Chan, Jason ;
Packman, Jeff ;
Wilson, Amy ;
Grogan, Donna R. .
NEUROLOGY, 2012, 79 (08) :785-792